Transcriptome-wide map of m⁶A circRNAs identified in a rat model of hypoxia mediated pulmonary hypertension

Hua Su, Guowen Wang, Lingfang Wu, Xiuqing Ma, Kejing Ying and Ruifeng Zhang*

Abstract

Background: Hypoxia mediated pulmonary hypertension (HPH) is a lethal disease and lacks effective therapy. circRNAs play significant roles in physiological process. Recently, circRNAs are found to be m⁶A-modified. The abundance of circRNAs was influenced by m⁶A. Furthermore, the significance of m⁶A circRNAs has not been elucidated in HPH yet. Here we aim to investigate the transcriptome-wide map of m⁶A circRNAs in HPH.

Results: Differentially expressed m⁶A abundance was detected in lungs of HPH rats. M⁶A abundance in circRNAs was significantly reduced in hypoxia in vitro. M⁶A circRNAs were mainly from protein-coding genes spanned single exons in control and HPH groups. Moreover, m⁶A influenced the circRNA–miRNA–mRNA co-expression network in hypoxia. M⁶A circXpo6 and m⁶A circTmtc3 were firstly identified to be downregulated in HPH.

Conclusion: Our study firstly identified the transcriptome-wide map of m⁶A circRNAs in HPH. M⁶A can influence circRNA–miRNA–mRNA network. Furthermore, we firstly identified two HPH-associated m⁶A circRNAs: circXpo6 and circTmtc3. However, the clinical significance of m⁶A circRNAs for HPH should be further validated.

Keywords: m⁶A circRNAs, Hypoxia mediated pulmonary hypertension, m⁶A circXpo6, m⁶A circTmtc3

Background

Pulmonary hypertension (PH) is a lethal disease and defined as an increase in the mean pulmonary arterial pressure ≥ 25 mmHg at rest, as measured by right heart catheterization [1]. Hypoxia mediated pulmonary hypertension (HPH) belongs to group III PH according to the comprehensive clinical classification of PH, normally accompanied by severe chronic obstructive pulmonary disease (COPD) and interstitial lung diseases [2]. HPH is a progressive disease induced by chronic hypoxia [1]. Chronic hypoxia triggers over-proliferation of pulmonary artery endothelial cells (PAECs) and pulmonary artery smooth muscle cells (PASMCs), and activation of quiescent fibroblasts, the hallmark of HPH [1, 3]. The pathological characteristics of HPH are pulmonary vascular remodeling, pulmonary hypertension, and right ventricular hypertrophy (RVH) [4]. So far there is no effective therapy for HPH [2]. More effective therapeutic targets are needed to be discovered.

Circular RNAs (circRNAs) were firstly found abundant in eukaryotes using RNA-seq approach [5–7]. Pre-mRNA is spliced with the 5′ and 3′ ends, forming a ‘head-to-tail’ splice junction, then circRNAs are occurred [5]. According to the genome origin, circRNAs may be classified into four different subtypes: exonic circRNA, intronic circRNA, exon–intron circRNA and tRNA introns circRNA [5]. circRNAs are reported to play crucial roles in miRNA binding, protein binding, regulation of transcription, and post-transcription [5, 8]. Recent reports indicated that circRNAs can translate to proteins [8, 9]. Moreover, circRNAs are widely expressed in human umbilical venous endothelial cells when stimulated by hypoxia [10, 11]. Up to date, only a few reports mentioned PH-associated circRNAs. circRNAs expression profile is demonstrated in HPH and chronic thromboembolic pulmonary hypertension [12]. However, the post-transcript modification of circRNAs in HPH is still unknown.

N⁶-methyladenosine (m⁶A) is regarded as one part of “epitranscriptomics” and identified as the most universal modification on mRNAs and noncoding RNAs (ncRNAs) in eukaryotes [13, 14]. DRm⁶ACH (D denotes A, U or G; R
Fig. 1 (See legend on next page.)
denotes A, G; H denotes A, C, or U) is a consensus motif occurred in m^6^A modified RNAs [15–17]. M^6^A modification is mainly enriched around the stop codons, at 3’ untranslated regions and within internal long exons [17–19]. Several catalyzed molecules act as “writers”, “readers”, and “erasers” to regulate the m^6^A modification status [14]. The methyltransferase complex is known as writers, including methyltransferase-like-3, −14 and −16 (METTL3/ METTL14/METTL16), Wilms tumor 1-associated protein (WTAP), RNA binding motif protein 15 (RBM15), vir like m^6^A methyltransferase associated (KIAA1429) and zinc finger CCCH-type containing 13 (ZC3H13), appending m^6^A on DRACH [17, 20, 21]. METTL3 is regarded as the core catalytically active subunit, while METTL14 and WTAP play a structural role in METTL3’s catalytic activity [18, 22]. The “erasers”, fat mass and obesity related protein (FTO) and alkylation repair homolog 5 (ALKB5H), catalyze the N-alkylated nucleic acid bases oxidatively demethylated [22]. The “readers”, the YT521-B homology (YTH) domain-containing proteins family includes YTHDF (YTHDF1, YTHDF2, YTHDF3), YTHDC1, and YTHDC2, specifically recognizes m^6^A and regulates splicing, localization, degradation and translation of RNAs [14, 22, 23]. The YTHDF1 and YTHDF2 crystal structures forms an aromatic cage to recognize m^6^A sites in cytoplasm [24]. YTHDC1 is the nuclear reader and YTHDC2 binds m^6^A under specific circumstances or cell types [24]. Hypoxia may alter the balance of writers-erasers-readers and induce tumor growth, angiogenesis, and progression [25, 26].

Interestingly, circRNAs can be m^6^A-modified. M^6^A circRNAs displayed cell-type-specific methylation patterns in human embryonic stem cells and HeLa cells [14]. CircRNAs contained m^6^A modifications are likely to promote protein translation in a cap-independent pattern [9]. However, m^6^A circRNAs has not been elucidated in HPH yet. Here we are the first to identify the expression profiling of m^6^A circRNAs in HPH.

**Results**

M^6^A level of circRNAs was reduced in HPH rats and most circRNAs contained one m^6^A peak

Three weeks treatment by hypoxia resulted in right ventricular systolic pressure (RVSP) elevating to 42.23 ± 1.96 mmHg compared with 27.73 ± 1.71 mmHg in the control (P < 0.001, Fig. 1a and b). The ratio of the right ventricle (RV), left ventricular plus ventricular septum (LV + S) [RV/ (LV + S)] was used as an index of RVH. RVH was indicated by the increase of RV/ (LV + S) compared with the control (0.25 ± 0.03 vs. 0.44 ± 0.04, P = 0.001, Fig. 1c). The medial wall of the pulmonary small arteries was also significantly thickened (19.28 ± 2.19% vs. 39.26 ± 5.83%, P < 0.001, Fig. 1d and e). Moreover, in the normoxia group, 53.82 ± 3.27% of the arterioles were non-muscularized (NM) vessels, and 25.13 ± 1.83% were fully muscularized (FM) vessels. In contrast, partially muscularized vessels (PM) and FM vessels showed a greater proportion (32.88 ± 3.15% and 41.41 ± 3.35%) in HPH rats, while NM vessels occupied a lower proportion (25.71 ± 2.55%) (Fig. 1f). Figure 1g displayed the heatmap of m^6^A circRNAs expression profiling in N and HPH. M^6^A abundance in 166 circRNAs was significantly upregulated. Meanwhile, m^6^A abundance in 191 circRNAs was significantly downregulated (Additional file 1: Data S1, filtered by fold change ≥4 and P ≤ 0.00001). Lungs of N and HPH rats were selected to measure m^6^A abundance in purified circRNAs. The m^6^A level in total circRNAs isolated from lungs of HPH rats was lower than that from controls (Fig. 1h). Moreover, over 50% circRNAs contained only one m^6^A peak either in lungs of N or HPH rats (Fig. 1i).

M^6^A circRNAs were mainly from protein-coding genes spanned single exons in N and HPH groups

We analyzed the distribution of the parent genes of total circRNAs, m^6^A-circRNAs, and non-m^6^A circRNAs in N and HPH, respectively. N and HPH groups showed a similar genomic distribution of m^6^A circRNAs and non-m^6^A circRNAs (Fig. 2a and b). Moreover, about 80% of m^6^A circRNAs and non-m^6^A circRNAs were derived from protein-coding genes in both groups. A previous report indicated that most circRNAs originated from protein-coding genes spanned two or three exons [14]. While in our study, over 50 and 40% of total circRNAs from protein-coding genes spanned one exon in N and HPH groups, respectively (Fig. 2c and d). Similarly,
Fig. 2 (See legend on next page.)
m^6A circRNAs and non-m^6A circRNAs were mostly encoded by single exons. Therefore, it was indicated that m^6A methylation was abundant in circRNAs originated from single exons in N and HPH groups.

**The distribution and functional analysis for host genes of circRNAs with differentially expressed m^6A peaks**

The length of differentially-expressed m^6A circRNAs was mostly enriched in 1–10,000 bps (Fig. 3a). The host genes of upregulated m^6A circRNAs were located in chromosome 1, 2, and 10, while the downregulated parts were mostly located in chromosome 1, 2 and 14 (Fig. 3b).

Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed to explore the host genes of circRNAs with differentially-expressed m^6A peaks. In the GO analysis (Fig. 3c, left), the parent genes of circRNAs with upregulated m^6A peaks were enriched in the protein modification by small protein conjugation or removal and macromolecule modification process in the biological process (BP). Organelle and membrane-bounded organelle were also the two largest parts in the cellular component (CC) analysis. Binding and ion binding were the two main molecular functions (MF) analysis. The top 10 pathways from KEGG pathway analysis were selected in the bubble chart (Fig. 3c, right). Among them, the oxytocin signaling pathway, protein processing in endoplasmic reticulum and cGMP-PKG signaling pathway were the top 3 pathways involved. In addition, vascular smooth muscle contraction pathway was the most associated pathway in PH progression [27].

In Fig. 3d left, the parent genes of circRNAs with downregulated m^6A peaks were mainly enriched in the cellular protein modification process and protein modification process in BP. Organelle and membrane-bound organelle made up the largest proportion in the CC classification. The MF analysis was focused on receptor signaling protein activity and protein binding. The parent genes of circRNAs with decreased m^6A peaks were mainly involved in the tight junction and lysine degradation in the KEGG pathway analysis (Fig. 3d, right).

**Hypoxia can influence the m^6A level of circRNAs and circRNAs abundance**

360 m^6A circRNAs were shared in N and HPH groups. 49% of m^6A circRNAs detected in N group were not detected in HPH group, and 54% of m^6A circRNAs detected in HPH group were not detected in N group (Fig. 4a). To explore whether m^6A methylation would influence circRNAs expression level, expression of the 360 common m^6A circRNAs were identified. More circRNAs tended to decrease in HPH compared to N (Fig. 4b). Moreover, expression of m^6A circRNAs was significantly downregulated compared with non-m^6A circRNAs in hypoxia, suggesting that m^6A may downregulate the expression of circRNAs in hypoxia (Fig. 4c, P = 0.0465).

**Construction of a circRNA–miRNA–mRNA co-expression network in HPH**

We found 76 upregulated circRNAs with increased m^6A abundance, and 107 downregulated circRNAs with decreased m^6A abundance (Fig. 5a, Additional file 2: Data S2, Additional files 3 and 4). As known, circRNAs were mostly regarded as a sponge for miRNAs and regulated the expression of corresponding target genes of miRNAs [28]. To explore whether circRNAs with differentially-expressed m^6A abundance influence the availability of miRNAs to target genes, we selected differentially-expressed circRNAs with increased or decreased m^6A abundance. GO enrichment analysis and KEGG pathway analysis were also performed to analyze target miRNAs. Target mRNAs displayed similar GO enrichment in the two groups (Fig. 5b and c). Two main functions were determined in BP analysis: positive regulation of biological process and localization. Intracellular and intracellular parts make up the largest proportion in CC part. Target mRNAs were mostly involved in protein binding and binding in MF part. In the KEGG pathway analysis, the top 10 most enriched pathways were selected (Fig. 5d and e). Wnt and FoxO signaling pathways were reported to be involved in PH progression [29–31]. Then, we analyzed the target genes involved in these two pathways. SMAD4 was associated with PH and involved in Wnt signaling pathways. MAPK3, SMAD4, TGFB1, and CDKN1B were involved in FoxO signaling pathways. To explore the influence of circRNA-miRNA regulation on PH-associated genes expression, we constructed a circRNA-miRNA-mRNA network, integrating matched expression profiles of circRNAs, miRNAs and mRNAs (Fig. 5f and g). MicroRNAs sponged by the target genes of interest were analyzed. MiR-125a-3p, miR-23a-5p, miR-98-5p, let-7b-5p, let-7a-5p, let-7g-5p, and miR-205 were analyzed because they were reported to be associated with PH [32, 33]. We filtered the key mRNAs and miRNAs, and founded that the two
Fig. 3 (See legend on next page.)
circRNAs were the most enriched, which were originated from chr1:204520403→204,533,534- (Xpo6) and chr7: 40223440→40,237,400- (Tmtc3).

M6A circXpo6 and M6A circTmtc3 were downregulated in PASMCs and PAECs in hypoxia

M6A abundance was significantly reduced in PASMCs and PAECs when exposed to hypoxia (0.107% ± 0.007 vs. 0.054% ± 0.118, \( P = 0.023 \) in PASMCs; 0.114% ± 0.011 vs. 0.059% ± 0.008, \( P = 0.031 \) in PAECs, Fig. 6a). M6A abundance in circRNAs was lower than it in mRNAs (0.1–0.4%) \[17, 18\]. Next, we confirmed the back-splicing of circXpo6 and circTmtc3 by CIRI software. The sequence of linear Xpo6 and Tmtc3 mRNA was analyzed. Then we identified that circXpo6 was spliced form exon 7, 8, and 9 of Xpo6. CircTmtc3 was spliced form exon 8, 9, 10, and 11 (Fig. 6b). Using cDNA and genomic DNA (gDNA) from PASMCs and PAECs as templates, circXpo6 and circTmtc3 were only amplified by divergent primers in cDNA, while no product was detected in gDNA (Fig. 6c). To identify whether circXpo6 and circTmtc3 were modified by m6A, we performed M6A RNA Immunoprecipitation (MeRIP)-RT-PCR and MeRIP-quantitative RT-PCR (MeRIP-qRT-PCR) to detect the expression of circXpo6 and circTmtc3 (Fig. 6d and e). m6A circXpo6 and m6A circTmtc3 were significantly decreased in PASMCs and PAECs when exposed to hypoxia (\( P = 0.002, \) and \( P = 0.015 \) in PASMCs and \( P = 0.02, \) and \( P = 0.047 \) in PAECs).

Discussion

In this study, we identified the transcriptome-wide map of m6A circRNAs in hypoxia mediated pulmonary hypertension. On the whole, we found that m6A level in circRNAs was reduced in lungs when exposed to hypoxia. M6A circRNAs were mainly derived from single exons of protein-coding genes in N and HPH. M6A abundance in circRNAs was downregulated in hypoxia in vitro. M6A influenced the circRNA–miRNA–mRNA co-expression network in hypoxia. Moreover, circXpo6 and circTmtc3 were the novel identified circRNAs modified by m6A in hypoxia mediated pulmonary hypertension.

M6A plays important roles in various biological processes. M6A is associated with cancer progression, promoting the proliferation of cancer cells and contributing to the cancer stem cell self-renewal \[18, 21\]. Lipid accumulation was reduced in hepatic cells when m6A abundance in peroxisome proliferator-activator (PPaR) was decreased \[34\]. Enhanced m6A level of mRNA contributed to compensated cardiac hypertrophy \[35\]. Also, m6A modification of large intergenic noncoding RNA 1281 was necessary for mouse embryonic stem cells differentiation \[36\].

Although it has been reported that m6A mRNAs were influenced by hypoxia, there is no report about m6A circRNAs in HPH yet. Up to now, no consistent conclusion was reached about the link between m6A and hypoxia. Previous reports found that the m6A abundance in mRNA was increased under hypoxia stress in HEK293T cells and cardiomyocytes \[37, 38\]. The increased m6A level stabilized the mRNAs of Glucose Transporter 1 (Glut1), Muc proto-oncogene bHLH transcription factor (Myc), Dual Specificity Protein Phosphatase 1 (Dusp1), Hairy and Enhancer of Split 1 (Hes1), and Jun Proto-Oncogene AP-1 Transcription Factor Subunit (Jun) without influencing their protein level \[37\]. In contrast, another reported that m6A level of total mRNA was decreased when human breast cancer cell lines were exposed to 1% \( O_2 \) \[26\]. Hypoxia increased demethylation by stimulating hypoxia-inducible factor (HIF)-1\( \alpha \)- and HIF-2\( \alpha \)-dependent over-expression of ALKBH5 \[26\]. In addition, transcription factor EB activates the transcription of ALKBH5 and downregulates the stability of METTL3 mRNA in hypoxia/reoxygenation-induced autophagy in ischemic diseases \[38\]. Our study found that m6A abundance in total circRNAs was decreased in hypoxia exposure. Moreover, our study indicated that circXpo6 and circTmtc3 were the novel identified circRNAs modified by m6A in HPH. M6A abundance in circXpo6 and circTmtc3 was decreased in hypoxia. It is probably because of HIF-dependent and ALKBH5-mediated m6A demethylation \[26\].

Previous reports indicated that m6A methylation close to 3'UTR and stop codon of mRNA is inversely correlated with gene expression \[14, 39\]. Low m6A level is negatively associated with circRNAs expression, while high m6A level is not linked to circRNAs expression in human embryonic stem cells and HeLa cells \[14\]. Consistent with the previous reports \[14, 39\], our study found that m6A reduced the total circRNAs abundance in hypoxia. The association between m6A level and specific gene abundance is remained as an open question. Some previous reports indicated that m6A level was positively associated with long non-coding RNA
Fig. 4 The relationship of m<sup>6</sup>A level and circRNAs abundance in hypoxia. (a) Venn diagram depicting the overlap of m<sup>6</sup>A circRNAs between N and HPH. (b) Two-dimensional histograms comparing the expression of m<sup>6</sup>A circRNAs in lungs of N and HPH rats. It showed that m<sup>6</sup>A circRNAs levels for all shared circRNAs in both groups. CircRNAs counts were indicated on the scale to the right. (c) Cumulative distribution of circRNAs expression between N and HPH for m<sup>6</sup>A circRNAs (red) and non-m<sup>6</sup>A circRNAs (blue). P value was calculated using two-sided Wilcoxon-Mann-Whitney test.
Fig. 5 (See legend on next page.)
(IncRNA) or mRNA expression [40, 41]. m^6^A was positively associated with RP11–138 J23.1 (RP11) expression when ALKBH5 was overexpressed in colorectal cancer [40]. miRNAs were downregulated after METTL14 deletion in β-cells [41]. On the contrary, another reports insisted that m^6^A level was negatively associated with RNA expression [42–44]. the mRNA lifetime of Family with Sequence Similarity 134, Member B (FAM134B) was prolonged when the m^6^A site was mutant [42]. The decreased m^6^A level resulted in the increased expression of N-methyl-D-aspartate receptor 1 (NMDAR1) in Parkinson’s disease [43]. Forkhead Box protein M1 (FOXM1) abundance was increased when ALKBH5 was upregulated in glioblastoma [44]. Our study indicated that the expression of circXpo6 and circTmtc3 was decreased with the downregulated m^6^A level. The association between m^6^A level and circRNAs abundance was not determined yet. We suspected that m^6^A may influence the expression of circXpo6 and circTmtc3 through similar manners as before [40, 41]. But it needs further validation.

Competing endogenous RNA (CeRNA) mechanism was proposed that miRNAs, pseudogenes, IncRNAs and circRNAs interact with each other by competitive binding to miRNA response elements (MREs) [45, 46]. m^6^A acts as a post-transcript regulation of circRNAs and influences circRNAs expression, thus we suggested that m^6^A could also regulate the circRNA–miRNA–mRNA co-expression network. When the circRNAs were classified, we found that these downstream targets regulated by circRNA–miRNA of interest were mostly enriched in PH-associated Wnt and FoxO signaling pathways [30, 31]. The Wnt/β-catenin (bC) pathway and Wnt/ planar cell polarity (PCP) pathway are the two most critical Wnt signaling pathways in PH [30].

As known, the two important cells associated with HPH are PASMCs and PAECs [1, 3]. The growth of PASMCs was increased when Wnt/bC and Wnt/PCP pathways were activated by platelet derived growth factor beta polypeptide b (PDGF-BB) [30, 47]. In addition, the proliferation of PAECs was enhanced when Wnt/bC and Wnt/PCP pathways were activated by bone morphogenetic protein 2 (BMP2). Furthermore, the FoxO signaling pathway is associated with the apoptosis-resistant and hyper-proliferative phenotype of PASMCs [31]. Reactive oxygen species is increased by hypoxia and activates AMPK-dependent regulation of FoxO1 expression, resulting in increased expression of catalase in PASMCs [48]. Our study firstly uncovered that m^6^A influenced the stability of circRNAs, thus affecting the binding of circRNAs and miRNAs, resulting in the activation of Wnt and FoxO signaling pathways.

**Conclusion**

In conclusion, our study firstly identified the transcriptome-wide map of m^6^A circRNAs in HPH. m^6^A level in circRNAs was decreased in lungs of HPH and in PASMCs and PAECs exposed to hypoxia. m^6^A level influenced circRNA–miRNA–mRNA co-expression network in HPH. Moreover, we firstly identified two downregulated m^6^A circRNAs in HPH: circXpo6 and circTmtc3. CircRNAs may be used as biomarkers because it is differentially enriched in specific cell types or tissues and not easily degraded [6]. Also, the aberrant m^6^A methylation may contribute to tumor formation and m^6^A RNAs may be a potential therapy target for tumor [17].

Limitations still exist in the study. First, we did not analyze the m^6^A level between circRNAs and the host genes. Second, the exact mechanism of hypoxia influences m^6^A was not demonstrated. Thirdly, the function of circXpo6 and circTmtc3 in HPH was not elaborated. Lastly, besides hypoxia mediated pulmonary hypertension, many other significant PH models should also be noted, such as monocrotaline mediated PH, monocrotaline + pneumonectomy mediated PH, and so on. It is insufficient that we explored the expression profiling of m^6^A circRNAs only in hypoxia mediated pulmonary hypertension. We plan to explore the expression profiling of m^6^A circRNAs in monocrotaline-induced PH and other PH models. Moreover, the clinical significance of m^6^A circRNAs for HPH should be further validated.

**Methods**

**Hypoxia mediated PH rat model and measurement of RVSP and RVH**

Sprague-Dawley rats (SPF, male, 180–200 g, 4 weeks) were obtained from the Animal Experimental Center of Zhejiang University, China. Rats were maintained in a normobaric normoxia (FiO2 21%, n = 6) or hypoxic chamber (FiO2 10%, n = 6) for 3 weeks [3, 49]. Rats were then anesthetized by intraperitoneal injection of 1% sodium pentobarbital (130 mg/kg) [50]. Then, rats were fixed in supine position on the board. All of the operations were performed after rats were
Fig. 6 (See legend on next page.)
anesthetized and became unconscious. RVSP was measured as below. Right ventricle catheterization was performed through the right jugular using a pressure-volume loop catheter (Millar) as the previous reports [49, 51]. After measurement of RVSP, all rats were put into a confined and transparent euthanasia device (to observe whether the rats were sacrificed), then 100% CO₂ was released into the device continuously until all the rats sacrificed. The criteria for sacrifice were that rats did not have spontaneous breath for 2–3 min and blink reflex. Then, heart tissues were removed and segregated. The ratio of [RV/ (LV + S)] was used as an index of RVH. Lung were removed and immediately frozen and segregated. The ratio of [RV/ (LV + S)] was used as an index of RVH. Lung tissues were embedded in paraffin, sectioned at 4 μm and stained with hematoxylin and eosin (H&E) and α-smooth muscle actin (α-SMA, 1:100, ab124964, Abcam, USA). The ratio of pulmonary small artery wall thickness and muscularization were calculated [3].

**Histological analysis**

Lung tissues were embedded in paraffin, sectioned at 4 μm and stained with hematoxylin and eosin (H&E) and α-smooth muscle actin (α-SMA, 1:100, ab124964, Abcam, USA). The ratio of pulmonary small artery wall thickness and muscularization were calculated [3].

**Isolation and hypoxia-treatment of PASMCs and PAECs**

PASMCs and PAECs were isolated using the methods according to previous reports [32, 50, 52]. PASMCs and PAECs were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) and 20% FBS for 48 h, respectively. Total RNA was extracted and treated by RNase R. m⁶A levels were determined as a percentage of total circRNAs. b Schematic representation of exons of the Xpo6 and Tmtc3 circularization forming circXpo6 and circTmtc3 (black arrow). c RT-PCR validation of circXpo6 and circTmtc3 in PASMCs and PAECs exposed to 21% O₂. Divergent primers amplified circRNAs in cDNA, but not in genomic DNA (gDNA). The size of the DNA marker is indicated on the left of the gel. d and e RT-PCR and qRT-PCR was performed after m⁶A RIP in PASMCs and PAECs exposed to 21% (N) and 1% O₂ (H) for 48 h, respectively. Input was used as a control (d). IgG was used as a negative control (d and e). Values are presented as means ± SD. *P ≤ 0.05 (different from 21% O₂ or the N-anti-m⁶A); **0.001 ≤ P ≤ 0.009 (different from the N-anti-m⁶A), (n = 3 each)

**RNA isolation and RNA-seq analysis of circRNAs**

Total RNA (10 mg) was obtained using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from lungs (1 g) of control and HPH rats. The extracted RNAs were purified with Rnase R (RNR07250, Epicentre) digestion to remove linear transcripts. Paired-end reads were harvested from Illumina Hiseq Sequence after quality filtering. The reads were aligned to the reference genome (UCSC RN5) with STAR software. CircRNAs were detected and annotated with CIRI software [55]. Raw junction reads were normalized to per million number of reads mapped to the genome with log2 scaled.

**MeRIP and library preparation**

Total RNA was extracted as the methods described above. Then, rRNA was depleted following DNase I treatment. RNase R treatment (5 units/mg) was performed in duplicate with 5 mg of rRNA-depleted RNA input. High-throughput m⁶A and circRNAs sequencing were performed by Cloudseq Biotech Inc. (Shanghai, China). Fragmented RNA was incubated with anti-m⁶A polyclonal antibody (Synaptic Systems, 202,003) in IPP buffer for 2 h at 4 °C. The mixture was then incubated with protein A/G magnetic beads (88,802, Thermo Fisher) at 4 °C for an additional 2 h. Then, bound RNA was eluted from the beads with N⁶-methyladenosine (PR3732, BERRY & ASSOCIATES) in IPP buffer and

---

**Table 1 Primers for RT-PCR or qRT-PCR**

| Name       | Sequence                        | Product size(bp) |
|------------|---------------------------------|------------------|
| linear Xpo6| Sense: 5’CTGTGTGGTGGTGCTCAGACG3’ | 199              |
|            | Antisense: 5’ATCGAGTTCTCTGACCTGC3’ |                 |
| linear Tmtc3| Sense: 5’ACCTGCGTGTACCAGGACC3’   | 203              |
|            | Antisense: 5’GAGAGAGGTAGTGCCGAGA3’ |                 |
| circXpo6   | Sense: 5’CTGGGAGAAGCAAGCAAG3’    | 101              |
|            | Antisense: 5’CAGGAGGGAGAGGCTG3’  |                 |
| circTmtc3  | Sense: 5’TACCCATGTCCAGAGGT3’     | 100              |
|            | Antisense: 5’GAAGCCAAGCATCCAGGA3’|                 |
extracted with Trizol reagent (15,596,026, Thermo Fisher). NEBNext Ultra ™ RNA Library Prep Kit (E7350L, NEB) was used to construct RNA-seq library from immunoprecipitated RNA and input RNA. The m⁶A-IP and input samples were subjected to 150 bp paired-end sequencing on Illumina HiSeq sequencer. Methylated sites on circRNAs were identified by MetPeak software.

Construction of circRNA–miRNA–mRNA co-expression network
The circRNA–miRNA–mRNA co-expression network was based on the ceRNA theory that circRNA and mRNA shared the same MREs [45, 46]. Cytoscape was used to visualize the circRNA–miRNA–mRNA interaction based on the RNA-seq data. The circRNA-miRNA interaction and miRNA–mRNA interaction of interest were predicted by TargetScan and miRanda.

Measurement of Total m⁶A, MeRIP-RT-PCR and MeRIP-qRT-PCR
Total m⁶A content was measured in 200 ng aliquots of total RNA extracted from PASMCs and PAECs exposed to 21% O₂ and 1% O₂ for 48 h using an m⁶A RNA methylation quantification kit (P-9005, Epigentek). MeRIP (17–701, Millipore) was performed according to the manufacturer's instruction. A 1.5 g aliquot of anti-m⁶A antibody (ABE572, Millipore) or anti-IgG (PP64B, Millipore) was conjugated to protein A/G magnetic beads overnight at 4 °C. A 100 ng aliquot of total RNA was then incubated with the antibody in IP buffer supplemented with RNase inhibitor and protease inhibitor. The RNA complexes were isolated through phenol-chloroform extraction (P1025, Solarbio) and analyzed via RT-PCR or qRT-PCR assays. Primers sequences are listed in Table 1.

Data analysis
3’ adaptor-trimming and low quality reads were removed by cutadapt software (v1.9.3). Differentially methylated sites were identified by the R MeTDiff package. The read alignments on genome could be visualized using the tool IGV. Differentially expressed circRNAs were identified by Student's t-test. GO and KEGG pathway enrichment analysis were performed for the corresponding parental mRNAs of the DE circRNAs. GO enrichment analysis was performed using the R topGO package. KEGG pathway enrichment analysis was performed according to a previous report [56]. GO analysis included BP, CC, and MF analysis. MicroRNAs sponged by the target genes were predicted by TargetScan and microRNA websites. P values are calculated by DAVID tool for GO and KEGG pathway analysis. The rest statistical analyses were performed with SPSS 19.0 (Chicago, IL, USA) and GraphPad Prism 5 software (La Jolla, CA). N refers to number of samples in figure legends. The statistical significance was determined by Student's t-test (two-tailed) or two-sided Wilcoxon-Mann-Whitney test. P < 0.05 was considered statistically significant. All experiments were independently repeated at least three times.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12864-020-6462-y.

Additional file 1: Data S1. Differentially expressed m⁶A abundance in circRNAs.

Additional file 2: Data S2. Differentially expressed m⁶A abundance linked with differentially expressed circRNAs abundance.

Additional file 3. Differentially expressed m⁶A circRNAs in the lungs of HPH rat model.

Additional file 4. Differentially expressed circRNAs in the lungs of HPH rat model.

Abbreviations
ALKBH5: Alkylation repair homolog 5; BMP2: Bone morphogenetic protein 2; BP: Biological process analysis; CC: Cellular component analysis; CeRNA: Competing endogenous RNA; circRNAs: Circular RNAs; COPD: Chronic obstructive pulmonary disease; Dusp1: Dual Specificity Protein Phosphatase 1; FAM134B: Family with Sequence Similarity 134, Member B; FOXM1: Forkhead Box protein M1; FTO: Fat mass and obesity related protein; Glut1: Glucose Transporter 1; GO: Gene ontology analysis; He1: Hairless and Enhancer of Split 1; HIF-1α, HIF-2α: Hypoxia-inducible factor-1α, 2α; HPH: Hypoxia mediated pulmonary hypertension; JUN: Jun Proto-Oncogene AP-1 Transcription Factor Subunit; KEGG: Kyoto Encyclopedia of Genes and Genomes; KIAA1429: Vir like m6A methyltransferase associated; LncRNA: Long non-coding RNA; m⁶A: N6-methyladenosine; MeRIP: M⁶A RNA Immunoprecipitation; MeRIP-qRT-PCR: MeRIP-quantitative RT-PCR; METTL13, METTL14, METTL16: Methyltransferase-like-3, –14 and –16; MF: Molecular functions analysis; MREs: MiRNA response elements; Myc: Myc proto-oncogene bHLH transcription factor; ncRNAs: Noncoding RNAs; NMDAR1: N-methyl-D-aspartate receptor 1; PAECs: Pulmonary artery endothelial cells; PASMCs: Pulmonary artery smooth muscle cells; PDGF-BB: Platelet derived growth factor beta polypeptide b; PH: Pulmonary hypertension; PPAR: Peroxisome proliferator-activator; RBM15: RNA binding motif protein 15; RP11: RP11–138.231.1; RVSP: Right ventricular systolic pressure; WTAP: Wilms tumor 1-associated protein; YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2: YTHDF2-1-B homology domain-containing proteins family; ZC3H13: Zinc finger CCCH-type containing 13
Ethics approval and consent to participate
The protocol of this research was submitted to and approved by the Institutional Animal Care and Use Committee of Zhejiang University, China (permit number: SYXX 2017–0006).

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 5 September 2019 Accepted: 8 January 2020
Published online: 13 January 2020

References
1. Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, Stenmark KR. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol. 2015;308:L239–52.
2. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;45(6):879–92.
3. Zhang RF, Shi LH, Zhou L, Zhang GS, Wu XH, Shao FC, et al. Transgelin as a therapeutic target to prevent hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306:L574–83.
4. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1alpha. Am J Respir Crit Care Med. 2014;189(3):314–24.
5. Meng X, Li X, Zhang P, Wang J, Zhou Y, Chen M. Circular RNA: an emerging key player in RNA world. Brief Bioinform. 2017;18(4):547–57.
6. Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(2):309–16.
7. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(9):1–8.
8. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep. 2017;21(11):2809–23.
9. Su H, Xu X, Yan C, Shi Y, Hu Y, Dong L, et al. Identification and characterization of hypoxia-regulated endothelial circular RNA. Circ Res. 2015;117(10):894–90.
10. Chen K, Lu Z, Wang X, Tu Y, Luo GZ, Liu N, et al. High-resolution N(6)-methyladenosine (m(6)a) mapping using photo-crosslinking-assisted m(6)a sequencing. Angew Chem. 2015;54(5):1587–90.
11. Wang J, Zhou MC, Kallioniemi O, Wang J, Chen J, Juvonen T, et al. CircRNA expression is linked to tissue-specific miRNA expression in lung tissues from mice with hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;303(6):L526–36.
12. Boecikel JN, Jae N, Heumuller AW, Chen W, Boon RA, Stellos K, et al. Identification and characterization of hypoxia-regulated endothelial circular RNA. Circ Res. 2015;117(10):894–90.
13. Zhang RF, Shi LH, Zhou L, Zhang GS, Wu XH, Shao FC, et al. Transgelin as a therapeutic target to prevent hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306:L574–83.
14. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1alpha. Am J Respir Crit Care Med. 2014;189(3):314–24.
15. Meng X, Li X, Zhang P, Wang J, Zhou Y, Chen M. Circular RNA: an emerging key player in RNA world. Brief Bioinform. 2017;18(4):547–57.
16. Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(2):309–16.
17. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(9):1–8.
18. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep. 2017;21(11):2809–23.
19. Su H, Xu X, Yan C, Shi Y, Hu Y, Dong L, et al. Identification and characterization of hypoxia-regulated endothelial circular RNA. Circ Res. 2015;117(10):894–90.
20. Chen K, Lu Z, Wang X, Tu Y, Luo GZ, Liu N, et al. High-resolution N(6)-methyladenosine (m(6)a) mapping using photo-crosslinking-assisted m(6)a sequencing. Angew Chem. 2015;54(5):1587–90.
21. Zhou C, Mollinie B, Daneshvar K, Pondick IV, Wang J, Van Wittenberghe N, et al. Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep. 2017;20(9):2662–75.
22. Zheng Y, Nie P, Peng D, He Z, Liu M, Xie Y, et al. m6AVar: a database of functional variants involved in m6A modification. Nucleic Acids Res. 2018;46(D1):D139–45.
23. Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, et al. RMBase v2.0: deciphering the map of RNA modifications from exome-transcriptome sequencing data. Nucleic Acids Res. 2018;46(D1):D327–34.
24. Wang S, Chai P, Jia R, Jia R. Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword. Mol Cancer. 2018;17(1):101.
25. Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018;9(2):124.
26. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of m6A methylation reveals enrichment in 3′UTRs and near stop codons. Cell. 2012;149(7):1635–46.
27. Wang X, Huang J, Zou Y, Yin P. Human m6A writers: two subunits, 2 roles. RNA Biol. 2017;14(3):300–4.
28. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(5):507–17.
47. JD JW, Austin ED, Gaskill C, Baskir R, Bilusova G, Jean JC, et al. Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2014;307:C415–30.

48. Awad H, Nolette N, Hinton M, Dakshinamurti S. AMPK and FoxO1 regulate catalase expression in hypoxic pulmonary arterial smooth muscle. Pediatr Pulmonol. 2014;49(9):885–97.

49. Cowburn AS, Crosby A, Macias D, Branco C, Colaco RD, Southwood M, et al. HIF2alpha-arginase axis is essential for the development of pulmonary hypertension. Proc Natl Acad Sci U S A. 2016;113(31):8801–6.

50. Yun X, Jiang HY, Lai N, Wang J, Shimoda LA. Aquaporin 1-mediated changes in pulmonary arterial smooth muscle cell migration and proliferation involve β-catenin. Am J Physiol Lung Cell Mol Physiol. 2017;313:L389–98.

51. Yamazato Y, Ferreira AJ, Hong KH, Siramula S, Francis J, Yamazato M, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension. 2009;54(2):365–71.

52. Xiao R, Su Y, Feng T, Sun M, Liu B, Zhang J, et al. Monocrotaline induces endothelial injury and pulmonary hypertension by targeting the extracellular calcium-sensing receptor. J Am Heart Assoc. 2017;6(4):e004865.

53. Zhang HY, Liu Y, Yan LX, Ou W, Zhang XD, Zhang M, et al. Bone morphogenetic protein-7 inhibits endothelial-mesenchymal transition in pulmonary artery endothelial cell under hypoxia. J Cell Physiol. 2018;233(5):4077–90.

54. Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Nogi M, et al. Protective roles of endothelial AMP-activated protein kinase against hypoxia-induced pulmonary hypertension in mice. Circ Res. 2016;119(2):197–209.

55. Thomas B, Hansen MTV, Christian K, Damgaard and Jørgen Kjems: comparison of circular RNA prediction tools. Nucleic Acids Res. 2015;44(6):e58.

56. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A. 2005;102(38):13544–9.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.